GSK's 2014 revenues fall but shares climb on upbeat respiratory talk
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline shares closed 2% up as investors were pleasantly surprised by better than expected earnings for the fourth quarter of 2014. As anticipated, total revenue for the year dropped 3% to £23.0bn following "challenging trading conditions particularly in the US primary care market," said CEO Sir Andrew Witty.